Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol

Acta Psychiatr Scand. 1998 Jun;97(6):458-66. doi: 10.1111/j.1600-0447.1998.tb10031.x.

Abstract

In a 4-week study of 14 drug-free schizophrenic patients (according to DSM-III-R), free and conjugated fractions of plasma homovanillic acid (pHVA) were repeatedly measured. Free HVA levels decreased during the first 2 h of haloperidol intake (P < 0.03). Conjugated HVA levels slowly decreased during the following weeks (P < 0.05), while free HVA levels remained stable. After 4 weeks, free HVA levels remained unchanged 2 h after morning haloperidol intake, but conjugated HVA levels tended to increase. In haloperidol responders, at baseline the free/total HVA ratio was significantly higher than that in non-responders (P < 0.01). Tolerant patients, i.e. those whose post-treatment free HVA levels decreased below pre-treatment levels, were not found to respond better to haloperidol than non-tolerant patients. The balance between free and conjugated pHVA may be a better reflection of the action of haloperidol than free pHVA levels and it may be of prognostic value in terms of drug response.

MeSH terms

  • Adult
  • Analysis of Variance
  • Antipsychotic Agents / blood
  • Antipsychotic Agents / pharmacology*
  • Antipsychotic Agents / therapeutic use
  • Dopamine Antagonists / blood
  • Dopamine Antagonists / pharmacology*
  • Dopamine Antagonists / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Resistance / physiology
  • Female
  • Haloperidol / blood
  • Haloperidol / pharmacology*
  • Haloperidol / therapeutic use
  • Homovanillic Acid / blood*
  • Humans
  • Longitudinal Studies
  • Male
  • Schizophrenia / blood*
  • Schizophrenia / drug therapy*
  • Severity of Illness Index
  • Time Factors
  • Treatment Outcome

Substances

  • Antipsychotic Agents
  • Dopamine Antagonists
  • Haloperidol
  • Homovanillic Acid